Equities research analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post ($0.09) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.13). Vanda Pharmaceuticals reported earnings of ($0.17) per share in the same quarter last year, which would suggest a positive year over year growth rate of 47.1%. The business is expected to announce its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Vanda Pharmaceuticals will report full-year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.81) to $0.13. For the next financial year, analysts expect that the business will report earnings of $0.68 per share, with EPS estimates ranging from $0.54 to $0.81. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. The company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44.00 million. During the same period last year, the company earned $0.08 earnings per share. The firm’s revenue was up 15.8% compared to the same quarter last year.
Vanda Pharmaceuticals stock traded down $0.10 during midday trading on Thursday, hitting $16.85. 643,546 shares of the stock were exchanged, compared to its average volume of 1,079,367. Vanda Pharmaceuticals has a 12 month low of $11.90 and a 12 month high of $20.40.
In related news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the transaction, the insider now directly owns 1,031,848 shares in the company, valued at $15,787,274.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Gunther Birznieks sold 8,568 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total transaction of $130,747.68. Following the transaction, the senior vice president now owns 118,366 shares in the company, valued at $1,806,265.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 287,506 shares of company stock worth $4,665,795. 7.60% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC acquired a new position in Vanda Pharmaceuticals during the fourth quarter worth $308,000. Metropolitan Life Insurance Co. NY acquired a new position in Vanda Pharmaceuticals during the fourth quarter worth $221,000. Macquarie Group Ltd. increased its holdings in Vanda Pharmaceuticals by 20.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock worth $34,484,000 after buying an additional 378,606 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in Vanda Pharmaceuticals by 5.1% during the fourth quarter. TIAA CREF Investment Management LLC now owns 446,482 shares of the biopharmaceutical company’s stock worth $6,787,000 after buying an additional 21,595 shares during the last quarter. Finally, Teachers Advisors LLC increased its holdings in Vanda Pharmaceuticals by 0.8% during the fourth quarter. Teachers Advisors LLC now owns 702,028 shares of the biopharmaceutical company’s stock worth $10,671,000 after buying an additional 5,690 shares during the last quarter. Institutional investors and hedge funds own 89.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3299334/analysts-anticipate-vanda-pharmaceuticals-inc-vnda-to-post-0-09-earnings-per-share.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.